Company registration number 14923629 (England and Wales)
SKIN & BONES MEDICAL LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
PAGES FOR FILING WITH REGISTRAR
SKIN & BONES MEDICAL LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
SKIN & BONES MEDICAL LIMITED
BALANCE SHEET
AS AT
30 JUNE 2025
30 June 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
6,581
7,588
Current assets
Stocks
400
311
Cash at bank and in hand
3,493
8,689
3,893
9,000
Creditors: amounts falling due within one year
4
(29,040)
(24,500)
Net current liabilities
(25,147)
(15,500)
Net liabilities
(18,566)
(7,912)
Capital and reserves
Called up share capital
5
100
100
Profit and loss reserves
(18,666)
(8,012)
Total equity
(18,566)
(7,912)

For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 17 April 2026 and are signed on its behalf by:
Dr J Lauder
Director
Company registration number 14923629 (England and Wales)
SKIN & BONES MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
- 2 -
1
Accounting policies
Company information

Skin & Bones Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is 1 Abbey Road, Whalley, Clitheroe, Lancashire, BB7 9RP.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Equipment
25% on cost
Fixtures and fittings
25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

SKIN & BONES MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 3 -
1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
0
3
Tangible fixed assets
Equipment
Fixtures and fittings
Total
£
£
£
Cost
At 1 July 2024
8,927
-
0
8,927
Additions
-
0
1,548
1,548
At 30 June 2025
8,927
1,548
10,475
Depreciation and impairment
At 1 July 2024
1,339
-
0
1,339
Depreciation charged in the year
2,232
323
2,555
At 30 June 2025
3,571
323
3,894
Carrying amount
At 30 June 2025
5,356
1,225
6,581
At 30 June 2024
7,588
-
0
7,588
4
Creditors: amounts falling due within one year
2025
2024
£
£
Other loans
28,320
23,900
Accruals and deferred income
720
600
29,040
24,500
SKIN & BONES MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 4 -
5
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
100
100
100
100
2025-06-30 2024-07-01 false false false 17 April 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Mr O OKafor Dr J Lauder 14923629 2024-07-01 2025-06-30 14923629 2025-06-30 14923629 2024-06-30 14923629 core:PlantMachinery 2025-06-30 14923629 core:FurnitureFittings 2025-06-30 14923629 core:PlantMachinery 2024-06-30 14923629 core:FurnitureFittings 2024-06-30 14923629 core:WithinOneYear 2025-06-30 14923629 core:WithinOneYear 2024-06-30 14923629 core:CurrentFinancialInstruments 2025-06-30 14923629 core:CurrentFinancialInstruments 2024-06-30 14923629 core:ShareCapital 2025-06-30 14923629 core:ShareCapital 2024-06-30 14923629 core:RetainedEarningsAccumulatedLosses 2025-06-30 14923629 core:RetainedEarningsAccumulatedLosses 2024-06-30 14923629 core:ShareCapitalOrdinaryShareClass1 2025-06-30 14923629 core:ShareCapitalOrdinaryShareClass1 2024-06-30 14923629 bus:Director2 2024-07-01 2025-06-30 14923629 core:PlantMachinery 2024-07-01 2025-06-30 14923629 core:FurnitureFittings 2024-07-01 2025-06-30 14923629 2023-06-08 2024-06-30 14923629 core:PlantMachinery 2024-06-30 14923629 core:FurnitureFittings 2024-06-30 14923629 2024-06-30 14923629 bus:OrdinaryShareClass1 2024-07-01 2025-06-30 14923629 bus:OrdinaryShareClass1 2025-06-30 14923629 bus:OrdinaryShareClass1 2024-06-30 14923629 bus:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 14923629 bus:SmallCompaniesRegimeForAccounts 2024-07-01 2025-06-30 14923629 bus:FRS102 2024-07-01 2025-06-30 14923629 bus:AuditExemptWithAccountantsReport 2024-07-01 2025-06-30 14923629 bus:Director1 2024-07-01 2025-06-30 14923629 bus:FullAccounts 2024-07-01 2025-06-30 xbrli:pure xbrli:shares iso4217:GBP